DBTX
Closed
Decibel Therapeutics Inc
4.91
0.00 (0.00%)
Last Update: 04 Oct 2023 16:30:00
Yesterday: 4.91
Day's Range: 4.91 - 4.91
Send
sign up or login to leave a comment!
When Written:
3.02
Decibel Therapeutics Inc is a biotechnology company that focuses on developing therapies to treat hearing and balance disorders. The company was founded in 2015 and is headquartered in Boston, Massachusetts.
Decibel Therapeutics' approach is to use a combination of genetics, drug discovery, and regenerative medicine to develop treatments for hearing and balance disorders. The company's pipeline includes potential therapies for various types of hearing loss, including sensorineural hearing loss, noise-induced hearing loss, and age-related hearing loss.
Decibel Therapeutics has partnerships with several pharmaceutical companies, including Regeneron Pharmaceuticals and Celgene Corporation. The company has also received funding from various sources, including the venture capital firm Third Rock Ventures and the National Institutes of Health.
Overall, Decibel Therapeutics is focused on developing innovative therapies to address the significant unmet medical need for hearing and balance disorders.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Decibel Therapeutics' approach is to use a combination of genetics, drug discovery, and regenerative medicine to develop treatments for hearing and balance disorders. The company's pipeline includes potential therapies for various types of hearing loss, including sensorineural hearing loss, noise-induced hearing loss, and age-related hearing loss.
Decibel Therapeutics has partnerships with several pharmaceutical companies, including Regeneron Pharmaceuticals and Celgene Corporation. The company has also received funding from various sources, including the venture capital firm Third Rock Ventures and the National Institutes of Health.
Overall, Decibel Therapeutics is focused on developing innovative therapies to address the significant unmet medical need for hearing and balance disorders.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








